نمحرلا هللا مسب management of ميحرلا status asthmaticus asthmmaticus...management...
TRANSCRIPT
Management of Status Asthmaticus
Management of Status Asthmaticus
Dr. Nasser HaidarMBBS, ABMS, KSUF, MRCP (UK), FPCCM
Senior Consultant Pediatric Critical Care
Associate Professor ; UST, [email protected]
الرحمن الله بسمالرحيم
Introduction
• Definition.• Epidemiology.• Pathophysiology
• Recognition.
• Management.
• Questions• Summary
What is Status Asthmaticus ?
Wheezing not responding to the
initial doses of nebulized bronchodilators
No specific definition
How big is the problem?
Hospital Admissions 500,000 (200,000)
Needed Intubation 1 – 20%
DeathsUp to 8% of MV
5000 / Year
Prevalence 10-30%
Hospitalization
Hospitalization
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
0
10
20
30
40
50
60
70
< 1 year
14 years
514 years
1524 years
Rat
e pe
r 10
,000
pop
ulat
ion
Hospital discharge rates for asthma
MMWR 1996;45(17):350-3
Mortality
Rates of death in children from asthma
Mannino. MMWR 1998;47(1):1-27
More in adults More in children
< 4 Y
< 4 Y
Adults
15-24
Risk factors for fatal asthmaDifficult to
identifyHistory ofED visitsIntubation/ventilation Psychosocial issuesNon-whiteObesityGenetic (response)
http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf
1/3 of deaths had only
mild asthma
Pathophysiology
Lazaar AL. Am J Med 2003;115:652, with modification
Airway remodelingEpith. injury
Subepith. fibrosis
Smooth muscle
hyperplasia
Mucous gland
hypertrophy
Goblet cell
hyperplasia
Mucus
Airway remodeling
Broncho-constriction with allergen challenge
Broncho-constriction with allergen challenge
Before
10 Minutes After
Allergen Challenge
Inflammation
Airway edema
Mucous blug
Spasm
Narrow airway
Premature closure
Air trapping Heterogene
ousV/Q mismatch
Hypoxemia
Hypercarpia
Sequence of Events
Dead space
Hypoxemia
Acidosis.
VC-Ve I.P. P.
LV
P. edema
Hyperinflation.
RV
Hypotension
Cardiopulmonary Interaction
Presentation &
Assessment of Severity
Presentation
Impending RF
Altered LOC Central cyanosis
Distant or absent breath sounds
Agitation or inability to lie down
Inability to speak, Sweating
Work of breathing Wheezing
Resp.Failure
Assessment of
Severity
Score RR Wheezing I:e ratio
Accessory
muscles.
Saturation.
0 ≤ 30 None 2:1 None 99-1001 31-45 End
Expiration
1:1 + 96-98
2 46-60 Entire Expiratio
n
1:2 ++ 93-95
3 >60 Inspiration Expiration
1:3 +++ <93
Pulmonary Index Score
≥ 5 Impending Resp. failure
Pulsus Paradoxus
Normal Drop in BP
during inspiration
Is ≤5
≥10 mmHg
Is PP
Capacitance of lung vessels.
LV afterload
Decr. C.O.
blood to LV
SV
Low BP
Peak Flow Rate
% State80 Normal70-80 Mild40-69 Mod.
<40 Severe
Age & Sex dependent
Assessment
Pulsus Paradox
us.
Clinical
Clinical
ClinicalPulmonar
y Index Score
Time consuming
PFR < 40%
(Cooperation)
Assessment
ABGBefore Beta2
agonist Respiratory Acidosis alone is not
Indication for intubation
Capnogram: NO Plateau
PreventionEducation
Early recognition.
Inhaler addictionSteroid phobia
Health System
Access
Aggressive
Correct use of inhalers
Treatment
General Supportive Measures
Not < 10-12 L/min
Euovolemia
Specific treatment
Nebulized Salbutamol
0.15 mg/kg
Minim. 2.5mg
Maxim. 5 mg
10 mg/h for 5-10 Kg
15 mg/h 10-20 Kg
20 mg/h > 20 Kg
Intermittent Continuous
Systematic Review
More effectiveNo extra S/E
10%10%0.15-0.5
mg/kg/hour
Steroids
Fanta CH: Am J Med 1983;74:845
Systemic Corticosteroids
Hydrocortisone4 mg/kg
2-4 mg/kg/dose
Optimal duration??????
Recent RCT 3 = 5 days
5-7 days for severe asthma
Methylprednisolone
2 mg/kg 0.5-1mg/kg/doseMeta-analysis No benefit with
higher doseActive or recent
exposure to chickenpox
Ibratropium bromide (Atrovent)
250 micg. for
< 20 Kg or < 6 Y
Then 500 micg.
Meta. 8 Ped. RCT Multiple doses decrease admission
by 25% (NNT = 4)Shorten Stay
Prolong duration of
Beta-2 agonist
Magnesium Sulfate
25-75 mg/kg over 20 minutes, max 2 g. Level
Meta. 5 Ped RCTDecr. Admissions
NNT = 4
Meta. Confirmed Efficacy & Safety
Meta. Adult. Inhaled MgSO4
Effective in severe cases
0
10
20
30
40
50
60
50 min 80 min 110 min
PlaceboMagnesium
Ciarallo L. J Pediatr 1996;129(6):809-14
Magnesium Sulfate
Salb
utam
ol
Nebul
izatio
n
Ibra
tropi
um
brom
ide
Mag
nesium
Sulfa
te
Ster
oidsWhat is next if no
improvement?
Parenteral Bronchodilators
Beta.2 Agonists OR
Aminophylline
Parenteral Bronchodilators
10 mcg/kg loading
0.1-10 mcg/kg/min
By 0.5 mic Q 30 min.
Bolus 15 mic/kg
OR
0.5-5 mcg/kg/min
Terbutaline Salbutamol
(Albuterol)
Better affinity
OR
AminophyllineMeta. 7 Ped. RCT
Improvement in clinical & PFT3 Ped RCT 30% Reduction in hospital
stay.Therapeuti
cLevel 10-20
mcg/ml
Side effects> 15
mcg/ml
Serious S/E
≥ 30
Achieve improvement or
Level of 15 mic/ml
Ove
rla
p
Contraindications of Theophylline
• Uncontrolled arrythmias• Uncontrolled Seizures• Peptic ulcer• Hyperthyroidism
Summary of Evidence
Therapy Strength of Recommenda
tion
Quality of Evidence
Short acting Beta2 a. Strong High
Systemic steroids Strong High
Magnesium sulf. Strong High
Anticholinergic Strong Moderate
IV Salbutamol Strong Moderate
Aminophylline Strong Moderate
Hypoxic orHypercarpi
a
Progressing
toward fatigue
Salb
uta
mol
Ibra
trop
ium
brom
ide
Mag
nesi
um
Sulfat
ePa
rent
eral
Bro
ncho
dila
tors
Amin
ophy
lline
Ster
oidsWhat is next?
You have to go through the difficult road
Positive Pressure
Ventilation
None Invasive Positive Pressure Ventilation
(NPPV)
NPPVSat. > 92% FiO2 <
70%PaCO2 < 45-50
mmHg
FiO2 > 70%PaCO2 > 50
mmHg
CPAP BiPAP8/5 12/8
Can NPPV be Applied to ALL
Patients?
NOCooperation Well fitted
mask
If NPPV Not suitable
or Failed !
Indications for Tracheal Intubation
Severe Hypoxemia
Severe WOB,
unable to speak, fatigue
Drop in LOC
Arrest
BUT
Be Ready with:
AdequateVenous access
Mon
itorin
gSedation
Able to manage DOPE &
Hypotension
Complications
10-50%
Goals of MVWOBAdequate
Oxygenation
Sufficient
Ventilation
PEEP
PRVCTV => plateau
<30Low rateLow Ti
I:e ratio 1:3-1:5High FR
Adjunctive Therapy“Rescue Therapy”
Cast
Adjunctive Therapy“Rescue Therapy”
Inha.GA ECMO
Propo
fol
Halothane or Isoflurane ?
Complications
Prognosis
MR Up to 8%
Of Intubated pts
QuestionsBefore the summary
Antibiotics
Bacterial or
Mycoplasma .
?
Heliox ?
• Meta. 3 Ped. RCT• Potential benefit• Facilitate drug delivery• Still not standard.
Leukotriene receptors
antagonists
Are you Going to Intubate
A child with:High respiratory effort.
Saturation 92%
PaCO2 55
pH 7.25
Unilaterally
dilated pupil!
Summary
If no response to first doses of N bet-2
a.
Aggressive pharmacothera
py
Dx. Of Severe Asthma is clinical
Summary
Magnes
ium
Sulfa
te
NPPV
if
suita
ble
Trach
eal
Intubation
GA
ECMOContinuous
Nebulization
SteroidsAtrovent Parenteral
Beta-2 agonist
Aminophyll.
SummaryTherapy Strength of
Recommendation
Quality of
EvidenceShort acting
Beta2 a.Strong High
Systemic steroids
Strong High
Magnesium sulf. Strong High
Anticholinergic Strong ModerateIV Salbutamol Strong Moderate
Aminophylline Strong Moderate
Key Points•Prevention is the best.•Early recognition of severity.
•Aggressive therapy• Very close observation.
•High threshold for intubation
Than
ks Th
ank
sThan
ks
Questions?
During the management of the patient in the PICU, he
developed acute renal failure.
What are the possible causes?